Connections between prolactin and ovarian cancer

Amira Alkharusi1*, Abdullah AlMuslahi1, Najwa AlBalushi1, Radiya AlAjmi2, Sami AlRawahi1, Asmaa AlFarqani1, Gunnar Norstedt3, Fahad Zadjali4

1 Department of Physiology, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman, 2 Department of Pathology, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman, 3 Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden, 4 Department of Biochemistry, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman

* akharusi@squ.edu.om

Abstract

Ovarian cancer (OC) is characterized by a high morbidity and mortality, highlighting a great need for a better understanding of biological mechanisms that affect OC progression and improving its early detection methods. This study investigates effects of prolactin (PRL) on ovarian cancer cells, analyzes PRL receptors (PRLR) in tissue micro arrays and relates PRLR expression to survival of ovarian cancer. A database, composed of transcript profiles from OC, was searched for PRLR expression and results were put in relation to survival. Expression of PRLR in OC tissue sections and OC cell lines SKOV3, OV2008 and OVSAHO was assessed using immunohistochemistry, western blots and quantitative real-time PCR. The biological function of PRLR was evaluated by proliferation, colony formation and wound healing assays. Levels of PRLR mRNA are related to survival; in epithelial OC a high PRLR mRNA expression is related to a shorter survival. Analysis of a tissue micro array consisting of 84 OC showed that 72% were positive for PRLR immuno-staining. PRLR staining tended to be higher in OC of high grade tumors compared to lower grades. PRLR mRNA and protein can further be detected in OC cell lines. Moreover, in vitro treatment with PRL significantly activated the JAK/STAT pathway. PRLR expression is associated with OC survivals. PRL and its receptor may play an onco-modulatory role and promote tumor aggressiveness in OC. Alternatively, increased PRLR levels may form a base for the development of PRLR antagonist or PRLR antagonist-drug conjugate to increase selective uptake of anti-cancer drugs.

Introduction

Ovarian cancer (OC) is often diagnosed at an advanced stage and is a major cause of morbidity and mortality in women worldwide with higher mortality compared to other gynecologic malignancies [1, 2]. Its occurrence tends to increase in younger women in recent years [3]. Despite advancements in surgical intervention, chemotherapy and radiotherapy, the survival rate of OC continues to be low and is associated with the tumor stage and the histological
tumor type with an overall relative survival of 65%, 44%, and 36% at 2, 5, and 10 years, respectively [4–6]. Serous ovarian carcinoma is the most common subtype of epithelial ovarian carcinoma accounting for 68–71% of all cases followed by endometrioid (9–11%), clear cell (12–13%), mucinous (3%) and transitional (1%) [7]. Most of OC cases are diagnosed in advanced stages due to a high invasive nature, lack of early symptoms, screening strategies and diagnostic markers. Trans-vaginal ultrasound and serum measurement of serum cancer antigen 125 (CA-125) are currently used as a screening test for the high-risk population. However, these screening modalities lacks selectivity toward malignant and benign tumors [8]. The sensitivity of serum CA-125 is less than 60% in early stages and when it is associated with ultrasound imaging, the positive predictive value (PPV) is improved by only 20% [9–11]. Other novel biomarkers for OC have not yet fulfilled criteria of sensitivity and specificity to be approved for clinical application [12].

An emerging role of prolactin (PRL) has been proposed in several different cancers including OC. Elevated serum PRL levels has been observed in all different stages of OC along with CA-125 [13]. Expression of the PRL receptor (PRLR), a member of the cytokine receptor family, is for unknown reasons shown to be high in OC [14]. Beside the well known function of PRL in mammary gland development and lactation, PRL stimulates proliferation of different cell types in the body [15, 16] and has been linked to enhanced tumor cell growth [17]. Increased PRLR levels in tumors may therefore be a sign of increased PRL stimulated cancer cell growth [18, 19]. Recent findings demonstrate that PRL production is not only restricted to the pituitary gland [20], and extra-pituitary PRL production may be of relevance in cancer. In humans and other primates, but not in rodents, research has demonstrated expression of the PRL gene in several extra-pituitary tissues [21, 22]. This is because of the presence of an alternative promoter located 5.8 kb upstream of the pituitary transcription start site which drives extra-pituitary PRL expression [23–26]. Although different promoters control PRL expression in pituitary and extra-pituitary tissues, the human PRL protein sequence is identical regardless of the site of production [27]. Extra-pituitary PRL is similar to the pituitary PRL. The mature form of the 23 kDa PRL protein consists of 199 amino acids in humans, and has four α-helixes arranged in an up-up-down-down style [28]. Other well-characterized 14-, 16-, 22-kDa prolactin protein variants are generated by proteolytic cleavage of the 23kDa protein [28].

Production is well recognized, and although studies indicate a proliferative/anti-apoptotic role for this autocrine/paracrine-produced PRL, the role of extra-pituitary PRL production in humans still requires further investigations [22]. Several publications suggest that activation of the PRL/PRLR signaling pathways is linked to cancer [29] via activation of JAK/STAT [19, 30], PI3K, AKT and MAPK pathways. Despite years of studies, there is still lack of effective diagnostic markers of sufficient sensitivity for clinical applications. There is an emerging need for OC studies to find new diagnostic/prognostic biomarkers and to find new therapeutic targets.

In the present study, we aimed to investigate the role of the PRL/PRLR axis by analyzing effects of PRL on OC cells in vitro and by analyzing OC tissue specimens for PRLR expression.

Materials and methods

Kaplan Meier plots

Kaplan-Meier survival plots were generated using an online database for ovarian cancers (www.kmplot.com/ovar) [31]. The database contains transcript profiles from epithelial ovarian cancer cases with defined histo-types (serous and endometrioid ovarian cancer). Data base searches were conducted using the search term prolactin receptor (PRLR), then jetset selects the optimal probe set for PRLR gene using a scoring method established to assess each probe set for specificity, coverage and degradation resistance. Based on this we selected the best
probes (227629-at) and Kaplan-Meier survival curves, related to PRLR mRNA expression were constructed for epithelial OC for 24 months survival time from 614 high grade- and 381 low grade- epithelial tumors. All cut-off values between upper and lower quartiles were tested and the best threshold was used to split the mRNA expression levels. A more descriptive analysis is described the provide website above.

Patient specimens and clinical data
Formalin Fixed Paraffin Embedded (FFPE) tissue sections from OC cases were purchased from US Biomax. Tissue Micro Array (TMA) sections with 12 cases of OC and 2 adjacent normal Ovarian (Biomax, USA, cat no. T112b) and TMA section with 72 cases of OC and 2 adjacent normal ovary tissue (Biomax, USA, cat no. BC11012b). Total number of ovarian tissue sections was 84. Breast cancer tissue sections served as a positive control.

Immunohistochemistry (IHC)
To investigate the expression of PRLR in human OC tissue sections, working conditions were optimized for heat-induced antigen retrieval, after deparaffinization and rehydration of tissue sections as described before [32]. For antigen retrieval, the slides were treated with citrate buffer; pH 6.0, (Nordic Biosite) in pressure cooker for 20 minutes and rinsed in Tris buffered saline containing 0.05% triton (TBST). Endogenous avidin and biotin were neutralized using the Avidin-Biotin Blocking Kit (Dako, USA) and endogenous peroxidase was blocked by 3% H2O2 (Histolab, Stockholm) for 15 minutes at room temperature (RT) in dark. Fc receptor was blocked by treating tissue sections with Fc receptor blocker 30 min, at 20˚C (Innovex Biosciences). Then tissue sections were incubated with targeted primary antibody diluted in a common antibody diluting buffer (BioGenix, USA) against PRLR, clone 1A2B1 (Invitrogen, USA) and incubated at 4˚C, overnight followed by washing and incubation with biotinylated anti mouse secondary antibody diluted according to the manufacturer’s instructions (BioGenix, USA) for 45 min at room temperature and incubation with streptavidin-biotin-peroxidase complex (BioGenix, USA). Haematoxylin was used for counterstaining. As negative control, the primary antibody was omitted from the staining procedure. Negative controls were performed in parallel to all experiments. IHC stained section analyzed by two independent pathologists at Sultan Qaboos University Hospital and considered the cytoplasmic staining for PRLR positive. The expression of PRLR was scored as described earlier [32]; negative (0% positive cells), mild expression: 1 (<24% positive cells), moderate expression: 2 (>25%-50% positive cells), and high expression: 3 (>50%-75% positive cells).

Cell lines and cell culture
The ovarian cancer cell lines SKOV3 and OV2008 were obtained from American Tissue Culture Collection (ATCC, USA). OVSAHO cells were established by Prof. Aikou Okamoto, Department of Obstetrics and Gynecology, Jikei University School of Medicine, Tokyo, Japan. SKOV3 cells were cultivated in McCoy’s 5A medium whereas OVSAHO and OV2008 were cultured in RPMI 1640 (Gibco, USA). All were cultured with media containing 10% Fetal Bovine Serum (FBS) (Gibco, USA), 100 U/ml penicillin and 100 μg/ml streptomycin (Gibco, USA) in a humidified 5% CO2 incubator at 37˚C. Treatment of cells with human recombinant PRL (a generous gift from Novo Nordisk A/S Denmark) was carried out as explained in each experiment. Breast cancer MCF-7 and glioma U251 cells were used as positive controls. All cells were treated with 200 ng/ml PRL. Pilot studies were carried for dose and time dependent experiments to establish the current PRL dose and time.
RNA extraction and quantitative real-time PCR (qRT-PCR)
RNasey Mini Kit (Qiagen, USA) was used according to manufacturer’s instructions to extract RNA from lysed cells. Random primers and the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, USA) was used to synthesize cDNA from extracted RNA samples. TaqMan Fast Universal PCR Master Mix (Life Technologies, USA) was used to quantify gene expression levels of the samples. The following specific TaqMan probe was used for PRLR (Hs01061477 m1, Thermofisher Scientific). The PCR was performed using a Fast Real-Time PCR system (7900HT, Applied Biosystems, USA). The endogenous control beta-2-microglobulin (B2M) (Life Technologies, USA) was used for normalization and relative expression was determined by the 2−ΔΔCt methods. Three separate experiments were performed. RNA samples from breast cancer (MCF7) and glioblastoma (U251) cells were used as positive control for PRLR expression [19].

Western blotting (WB)
SKOV3, OVSAHO and OV2008 cells were treated with human recombinant PRL (200ng/mL) for 20 minutes as previously described [19]. Cells were lysed with RIPA buffer (150 mM sodium chloride, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and 50 mM Tris, pH 8.0). Proteins were separated on a NuPAGE 4–12% Bis Tris gel (Thermofisher Scientific, USA), transferred to a PVDF membrane (Millipore), and blotted with antibodies against PRLR (cat# ab170935, Abcam, UK), STAT3/STAT5 (Cell Signaling, USA) and GAPDH (Sigma Aldrich, Germany) for all cells.

Alamar Blue assay
Alamar Blue (Invitrogen) was used to test the effect of PRL on proliferation of SKOV3, OVSAHO and OV2008 cells. Standard Alamar Blue protocol was followed. Cells were cultured in 96-well plate (Corning) in serum free media one day before PRL treatment and cells proliferation was assessed after 48 hours exposure to PRL. Thereafter, Alamar Blue was added for three hours and absorbance was read by the Thermo Scientific Multiscan Spectrum at 570/600 nm and compared to the non-treated control cells. The viability of the control cells was set as 100%.

Colony formation assay
SKOV3 and OV2008 were seeded at a density of 1,000 cells/well and OVSAHO at 5,000 cells/well in a 6-well culture plate (Corning) containing pre-warmed growth media. The plate was gently rotated to uniformly disperse the cells and incubated overnight. Next day, a dose of 200 ng/ml of PRL was added in serum free media to the treated cells. After two days of treatment, media was replaced with growth media and incubation was resumed. Post two weeks, macroscopic clones were carefully washed twice with DPBS (Gibco) and colonies were stained with crystal violet solution for 10–20 min. The staining solution was slowly washed away by immersing the plate in a water-containing pot multiple times. The plate was allowed to air dry and colonies were imaged and counted using Image J (NIH, USA).

In vitro wound healing migration assay
Cells were seeded in 12-well plates (Corning) in triplicates for 24 h and a vertical scratch was introduced by a sterile pipet tip followed by washing to remove un-attached cells. Cells were incubated for 48 hrs with 200ng/ml PRL. The scratch closure was imaged using an inverted light microscope. The analysis of the scratch images was performed by calculating the scratch
distance in μm (= open wound distance) for each image. The percentage of healing distance was plotted over time for each cell type before and after treatment. Data are presented as mean ± SE.

Statistical analysis
Cell culture experiments were performed in triplicates in at least three independent experiments. Statistical significance of the differences was evaluated using unpaired, 2-tailed Student’s t-test, ANOVA test with post-hoc analysis, and was considered significant when the significance level of the test was p < 0.05.

Results
Increased PRLR expression associated with short survivals in OC patients
Different PRLR markers of OC prognosis have been identified using literature search. Best jet set probes for gene expression analysis of PRLR was evaluated using a website (www.kmplot.com/ovar). A scoring method, established by this website, was used to assess each probe set for specificity, coverage and degradation resistance. Based on this we selected (227629-at) as the best probe. This probe (227629-at) was used to relate PRLR expression to survival using Kaplan-Meier curves. The data consisted of epithelial OC with up to 24 months survival time from 614 high grade- and 381 low-grade epithelial tumors (Fig 1). The survival plots depict lower progression-free survival with higher expression of PRLR in high grade tumor (Hazard ratio = 1.47, P-value <0.05) and low grade tumor (Hazard ratio = 1.68, P-value <0.05) as illustrated in (Fig 1A and 1B).

A Kaplan-Meier plots were generated using an online database for ovarian cancers (www.kmplot.com/ovar). Transcript profiles from 614 high grade- and 381 low grade- epithelial ovarian cancers were examined. The expression of PRLR mRNA related to survival is shown in the figure in the form of Kaplan-Meier survival curves. Fig 1A and 1B shows the survival plots depict lower progression-free survival with higher expression of PRLR in high grade tumor (Hazard ratio = 1.47, P-value <0.05) and low grade tumor (Hazard ratio = 1.68, P-value <0.05). Obviously patient’s survival decrease with increased PRLR expression.

![Fig 1. Kaplan Meier survival curve based on PRLR mRNA expression.](https://doi.org/10.1371/journal.pone.0255701.g001)
PRLR expression in ovarian cancer cells

We examined the PRLR transcript levels in three different OC cell lines SKOV3, OVSAHO and OV2008 cells. MCF7 and U251 cells were used as positive controls [19]. PRLR mRNA was 500–8000 fold higher in MCF-7 and U251 cells, p-value < 0.05, compared to OCs. In OC, PRLR mRNA expression was relatively higher in OVSAHO compared to the other OC cell lines, p-value < 0.05 (Fig 2A and 2B). PRLR protein was detected in all OC cell lines (Fig 2C). PRLR protein findings are in line with the mRNA expression levels.

PRLR expression in human OC tissue sections

Tissue microarrays (TMAs) consisting of 84 tissue samples from OC patients were analyzed by immuno-histochemistry to detect expression of PRLR (Fig 3). Two independent

![Graphs showing PRLR mRNA and protein expression](https://doi.org/10.1371/journal.pone.0255701.g002)

Fig 2. Increased PRLR transcript and protein expressions in ovarian cancer (OC) cells. A) PRLR mRNA expression levels in 3 ovarian cancer cell lines SKOV3, OVSAHO and OV2008 and two positive control cells; breast cancer cells (MCF7) and brain tumours cells (U251). B) Subsection of Fig 2A, to show relative expression between the three OC cell lines. Gene expression levels are reported as fold change with reference to the expression in SKOV3 cells. Results are representative of three separate experiments. Data is presented as mean ± SD (n = 3). Statistical significance is indicated as *P < 0.05. C) PRLR protein expression in OC cell lines and the positive controls. The long isoform of PRLR was expressed at 90kDa with highest protein expression in the OVSAHO cells.

[https://doi.org/10.1371/journal.pone.0255701.g002](https://doi.org/10.1371/journal.pone.0255701.g002)
pathologists analyzed the tissue sections for detection of expression and also categorized expression intensity as mild, moderate or high. Out of 84 samples on each tissue sections, 23 samples were negative (27%) and 61 were positive (72%) for PRLR (Fig 3A). Forty samples have mild (<25% of cells) expression of PRL (50%), a moderate level (25–50% of cells) was found in 11 patients (12%) and a high level (>50% of cells) was found in 10 patients (11%). Percentages of PRLR positive cells were also shown in OC patients with moderate and high-grade tumour. Mild PRLR staining was detected in 30% of high-grade tumors and 20% of low-grade tumors, moderate level in 6% of high-grade tumors and 7% of low-grade tumors and high-level staining level was found in 7% of high-grade tumors and 5% of low-grade tumors. All percentages were obtained by two independent pathologist and presented with 95% confidence intervals.

https://doi.org/10.1371/journal.pone.0255701.g003

Fig 3. Prolactin receptor immuno-reactivity in ovarian cancer tissues. Histological analyses of a tissue microarray (TMA) with 84 ovarian cancer (OC) and normal ovarian tissues as a control. A) PRLR immuno reactivity was detected in 61 out of 84 OC patients (72%) while 23 patients were negative (27%). B) PRLR staining in OC tissues; a mild level of PRLR staining (<25% of cells) was detected in 44 out of 84 patients (50%), a moderate level (25–50% of cells) was found in 11 patients (12%) and a high level (>50% of cells) was found in 10 patients (11%). C) Percentages of PRLR positive cells were also shown in OC patients with moderate and high-grade tumour. Mild PRLR staining was detected in 30% of high-grade tumors and 20% of low-grade tumors, moderate level in 6% of high-grade tumors and 7% of low-grade tumors and high-level staining level was found in 7% of high-grade tumors and 5% of low-grade tumors. All percentages were obtained by two independent pathologist and presented with 95% confidence intervals.
PRL induces STAT3/STAT5 phosphorylation in ovarian cancer cells

The short-term effect of PRL on intracellular protein phosphorylation was tested in OC cells (Fig 5). OC cells were treated with two concentrations of PRL (200 and 400 ng/ml) for 20 minutes. OV2008 cells showed constitutively active STAT5 phosphorylation without PRL and this activity increased with PRL treatment. PRL clearly increased STAT5 phosphorylation in OVSAHO cells (Fig 5). STAT5 levels were low in SKOV3 cells and we could not demonstrate any PRL effect on STAT5 phosphorylation. However, when STAT3 activity was measured in SKOV3 cells we could demonstrate increased STAT3 phosphorylation using 200 ng/ml of PRL (Fig 5) while no STAT3 phosphorylation was detected in OV2008 and OVSAHO cells.

PRL promotes migration and colony formation but not proliferation of OC cells

To further investigate the functional effect of PRL on the biological behavior of OC cells, proliferation, migration and colony formation assays were conducted. PRL treatment for 48 hours did not induce proliferation of OC cells under the test conditions used. However, there was a
significant increase in the migration of the three cell types after 48 hrs of PRL treatment (p-value < 0.05), (Fig 6A and 6B). The colony formation rate was assessed after PRL treatment in all cell lines (Fig 6C). PRL significantly increased the colony formation rate in all cell types. These findings indicated that PRL affects the biological behavior of OC cells.

Discussion

In this study we extracted data on epithelial OC cases and calculated the PRLR expression in relation to survival using Kaplan-Meier survival curves. We found that high PRLR expression in OC is associated with shorter survivals. By using immuno-histochemistry we further demonstrated PRLR expression in OC tissue sections. PRLR expression in cultured OC cells is detectable both at mRNA and protein levels and PRL treatment of cultured OC cells increased cell migration and colony formation rates.

Two different pathological approaches were used for immuno-histochemical analysis of tissue sections, namely staining intensity and percentage of stained malignant cells. Both approaches revealed heterogenous expression of PRLR in OC sections. More than 50% of OC tissue sections expressed PRLR at a low level using either of the pathological approaches. The remaining tissue sections varied from moderate to high expression. A marked and heterogeneous elevation in PRLR was previously reported in other types of tumors including breast cancer [33], prostate cancer [34], hepatocellular carcinoma [35] and glioblastoma multiforme [19].

Analysis of OC sections with high grade or low grade tumors, showed diverse expression in both grades. Negative PRLR expression was seen mostly in high-grade OC tumors but the tissue array had fewer (33 cases out of 84) of low-grade samples. No significant association was detected between PRLR expression levels and OC tumor grade (P-value >0.05). Such a non-

![Fig 5. Prolactin signaling in ovarian cancer cells.](https://doi.org/10.1371/journal.pone.0255701.g005)
significant association has been reported in other cancers such as hepatocellular carcinoma [27] and breast cancer [36]. When a database consisting of OC transcript profiles were used to relate PRLR expression to survival it was evident that PRLR expression is associated to survival rate. It is here relevant to point out that OC exist in different forms and further analysis could better related PRRR expression to different forms of OC. Analysis of OC sections against STAT3/STAT5 were not done in this study but previous supported showed increased STATs
expressions in OC tissues. In ascites derived OC cells, increased p-STAT3 levels were detected in 90–95% of the patients [37]. Also, expression of p-STAT3 and p-STAT5 but not p-STAT1 and p-STAT6, were significantly higher in ovarian cancer cells compared to benign and normal tissues [38]. Similar findings were also observed in p-STAT3 and total STAT3 in ovarian cancer tissues compared to benign and normal tissues [39].

In addition to the above findings, we found detectable levels of PRLR, mRNA and protein levels in three different OC cell lines and at a concentration of 200 ng/ml, PRL was shown to promote JAK/STAT activation in all OC cells. The STAT3/5 regulation by PRL observed in this study supports previous studies showing activation of these transcription factors in different types of cancer cells and the effect is cell-dependent [19, 29, 32]. It had been also shown that PRL induces production of different cytokines in murine peritoneal macrophages, including interleukin-1β (IL-1β), interleukin-12β (IL-12β), interferon-γ (IFN-γ), and TNF [40]. An autocrine loop of PRL signaling may enhance the inflammatory response of activated monocytes [41]. According to previous studies, the concept of locally produced PRL, which can activate its receptor on target cells, has emerged as a new mechanism in chronic inflammatory diseases and several hormone sensitive cancer models [42–44].

STAT5 is a transcription factor that is activated by PRL and phosphorylation of this protein has an anti-apoptotic role in cells. Previous studies have shown that phosphorylated STAT5 mediate oncogenic effects of EGFR in different tumor tissues [45–47]. In this study, OV2008 cell line showed constitutive STAT5 activation and this is because OV2008 cells are an ovarian cancer cells shown to have constitutive active pathways like PTEN, mTOR and Akt [48, 49]. This could be explained the p.E545K mutation in PIK3CA gene; this variant lies within the helical domain of the p110α protein that is linked a constitutive active signaling pathways [50, 51]. Collectively, all these findings support a concept that PRL and its receptor can have a significant role in OC pathogenesis.

Furthermore we showed increased migration and colony formation properties of OC cells with PRL treatment. However, in our hands PRL is not a strong mitogenic factor by itself and this seems to be the case also in our previous studies concerning glioblastoma [19] and leiomyoma cells [52]. It is fair statement that the precise role of PRL and its receptor in tumor biology is not yet clear but the present results taken together with previous investigations support a role for PRL/PRLR as being an onco-modulatory factor. Findings of increased PRLR levels in tumors combined with a frequently observed elevation of serum PRL in cancer patients formed the basis for a clinical trial to suppress serum PRL with dopamine receptor agonists. However, such treatment failed to demonstrate significant effects on tumor growth [53]. Moreover, due to the more recent demonstration of PRL production outside the pituitary gland, attempts have been made to block PRL by using PRLR antagonists (PRLRA) [54]. It has been shown that PRL variants acting as competitive PRLR antagonists can efficiently down regulate PRLR signaling, cell survival, and/or proliferation in various breast or prostate cancer preclinical assays [43, 44]. Moreover, PRL mRNA expression in the synovial tissue of rheumatoid arthritis patients positively correlates with several clinical disease parameters, which confirm the local PRL effect on disease pathogenesis.

A PRLR blocking monoclonal antibody showed significant antitumor activity against MCF7 breast cancer xenografts [55]. Our previous study in glioblastoma demonstrated increased PRLR expression levels and indicated some efficacy to reduce tumor cell growth by using PRLRA in experimental systems. Although a phase I clinical trial with PRLR neutralizing antibodies (LFA102) in breast or prostate cancer patients showed no antitumor activity when used as monotherapy [56], a lot of studies supported the rationale of using this approach in chronic inflammatory diseases like rheumatoid arthritis [57].
Future studies are needed to better clarify roles of PRL in different types of tumors and to explore the potential use of PRLRA as a novel therapeutic approach in different disease models. In conclusion, the current study showed that PRL and its receptor exert an onco-modulatory role in OC and blocking this receptor suggests a new line of anticancer treatments. Alternatively, increased PRLR levels may form the bases for the creation of drugs conjugated to PRLR antagonists to increase selective uptake of anti-cancer drugs.

Supporting information
S1 Fig. (PDF)

Author Contributions
Conceptualization: Amira Alkharusi, Gunnar Norstedt.
Data curation: Fahad Zadjali.
Formal analysis: Radiya AlAjmi, Fahad Zadjali.
Funding acquisition: Amira Alkharusi.
Investigation: Radiya AlAjmi, Asmaa AlFarqani.
Methodology: Abdullah AlMuslahi, Najwa AlBalushi, Sami AlRawahi, Asmaa AlFarqani, Fahad Zadjali.
Project administration: Amira Alkharusi.
Software: Najwa AlBalushi.
Supervision: Amira Alkharusi.
Validation: Amira Alkharusi, Gunnar Norstedt.
Writing – original draft: Amira Alkharusi.
Writing – review & editing: Abdullah AlMuslahi, Najwa AlBalushi, Radiya AlAjmi, Sami AlRawahi, Asmaa AlFarqani, Gunnar Norstedt, Fahad Zadjali.

References
1. Siegel R. Cancer Statistics. Ca Cancer Journal. 2017; 67: 7–30. https://doi.org/10.3322/caac.21387 PMID: 28055103
2. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer. John Wiley & Sons, Ltd; 2010; 127: 2893–2917. https://doi.org/10.1002/ijc.25516 PMID: 21351269
3. Lee JY, Kim EY, Jung KW, Shin A, Chan KKL, Aoki D, et al. Trends in gynecologic cancer mortality in east asian regions. Journal of Gynecologic Oncology. 2014; 25: 174–182. https://doi.org/10.3802/jgo.2014.25.3.174 PMID: 25045429
4. Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, et al. Ten-year relative survival for epithelial ovarian cancer. Obstetrics and Gynecology. 2012; 120: 612–618. https://doi.org/10.1097/AOG.0b013e318264f794 PMID: 22914471
5. Karimi-Zarchi M, Mortazavizadeh SMR, Bashardust N, Zakerian N, Zaidabadi M, Yazdian-Anari P, et al. The Clinicopathologic Characteristics and 5-year Survival Rate of Epithelial Ovarian Cancer in Yazd, Iran. Electronic physician. 2015; 7: 1399–406. https://doi.org/10.14661/1399 PMID: 26516450
6. Urban RR, He H, Alfonso R, Hardesty MM, Gray HJ, Goff BA. Ovarian cancer outcomes: Predictors of early death. Gynecologic Oncology. 2016; 140: 474–480. https://doi.org/10.1016/j.ygyno.2015.12.021 PMID: 26745351
7. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. England; 2011; 43: 420–432. https://doi.org/10.1097/PAT.0b013e328348a667 PMID: 21716157
8. Myers ER, Bastian LA, Havrilovsky LJ, Kulasingam SL, Terplan MS, Cline KE, et al. Management of adnexal mass. Evidence report/technology assessment. 2006; 1–145. https://doi.org/10.1097/AOG.0b013e318230ded3 PMID: 17854238
9. Jacobs LJ, Menon U. Progress and Challenges in Screening for Early Detection of Ovarian Cancer. Molecular & Cellular Proteomics. 2004; 3: 355–366. https://doi.org/10.1074/mcp.R400006-MCP200 PMID: 14764655
10. Wilder JL, Pavlik E, Straughn JM, Kirby T, Higgins RV, DePriest PD, et al. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation. Gynecologic oncology. United States; 2003; 89: 233–235.
11. Olivier RI, Lubsen-Brandisma MAC, Verhoef S, van Beurden M. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecologic oncology. United States; 2006; 100: 20–26. https://doi.org/10.1016/j.ygyno.2005.08.038 PMID: 16188302
12. Zhang W, Lei P, Dong X, Men X. Advances in tumor markers of ovarian cancer for early diagnosis. Indian Journal of Cancer. 2014; 51: 72. https://doi.org/10.4103/0019-509X.154049 PMID: 25818738
13. Mor G, Visentin I, Lai Y, Zhao H, Schwartz P, Rutherford T, et al. Serum protein markers for early detection of ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. National Academy of Sciences; 2005; 102: 7677–7682. https://doi.org/10.1073/pnas.0502178102 PMID: 15890779
14. Clendenen TV, Arslan AA, Lokshin AE, Liu M, Lundin E, Koenig KL, et al. Circulating prolactin levels and risk of epithelial ovarian cancer. Cancer causes & control: CCC. 2013/02/03 ed. 2013; 24: 741–748. https://doi.org/10.1007/s10552-013-0156-6 PMID: 23378139
15. Ruffion A, Al-Sakkaf KA, Brown BL, Eaton CL, Hamdy FC, Dobson PRM. The Survival Effect of Prolactin on PC3 Prostate Cancer Cells. European Urology. Elsevier; 2003; 43: 301–308. https://doi.org/10.1016/0302-2838(03)00038-1 PMID: 12600435
16. Ben-Jonathan N, Liby K, McFarland M, Zinger M. Prolactin as an autocrine/paracrine growth factor in human cancer. Trends in Endocrinology & Metabolism. Elsevier; 2016; 13: 245–250. https://doi.org/10.1016/S1043-2760(02)00603-3
17. Levina VV, Nolen B, Su Y, Godwin AK, Fishman D, Liu J, et al. Biological Significance of Prolactin in Gynecological Cancers. Cancer research. 2009; 69: 5226–5233. https://doi.org/10.1158/0008-5472.CAN-08-4652 PMID: 19491263
18. Alkharusi Amira, Yu Shengze, Landázuri Natalia Natalia, zadjali Fahad, Davoudi Belghis, Nystrom Thomas, et al. Stimulation of prolactin receptor induces STAT-5 phosphorylation and cellular invasion in Glioblastoma Multiforme. Oncotarget. 2016; 7. https://doi.org/10.18632/oncotarget.12840 PMID: 27788487
19. Christsensen HR, Murawsky MK, Horsemann ND, Willson TA, Gregerson KA. Completely humanizing prolactin rescues infertility in prolactin knockout mice and leads to human prolactin expression in extrapituitary mouse tissues. Endocrinology. 2013; 154: 4777–4789. https://doi.org/10.1210/en.2013-1476 PMID: 24029242
20. Ben-Jonathan N, Marshon JL, Allen DL, Steinmetz RW. Extrapituitary prolactin: Distribution, regulation, functions, and clinical aspects. Endocrine Reviews. 1996; 17: 639–689. https://doi.org/10.1210/edrv-17-6-638 PMID: 8969972
21. Ben-Waer M, Martial J A, Davis JR. Characterization of an up-stream promoter directing extrapituitary expression of the human prolactin gene. Molecular endocrinology (Baltimore, Md). 1994; 8: 365–42. https://doi.org/10.1210/mend.8.3.8058071 PMID: 8058071
22. Gellersen B, Kempf R, Telgmann R, DiMattia GE. Nonpituitary human prolactin gene transcription is independent of Pit-1 and differentially controlled in lymphocytes and in endometrial stroma. Molecular Endocrinology. 1994; 8: 356–373. https://doi.org/10.1210/mend.8.3.8015553 PMID: 8015553
23. Nevalainen MT, Valve EM, Ingleton PM, Nurmi M, Martikainen PM, Härkönen PL. Prolactin and prolactin receptors are expressed and functioning in human prostate. Journal of Clinical Investigation. 1997; 99: 618–627. https://doi.org/10.1172/JCI119204 PMID: 9045863
26. Tseng L, Mazella J. Prolactin and its receptor in human endometrium. Seminars in Reproductive Endocrinology. 1999; 17: 23–27. https://doi.org/10.1016/S0739-161X(99)80016-0

27. Sinha YN. Structural variants of prolactin: Occurrence and physiological significance. Endocrine Reviews. 1995. pp. 354–369. https://doi.org/10.1210/edrv-16-3-354

28. Kanyicska L, Lerant A, Freeman ME, Marc E. Prolactin: Structure, Function, and Regulation of Secretion MOLECULAR BIOLOGY. Physiological Reviews. 2000; 80: 1523–1631. Available: http://www.ncbi.nlm.nih.gov/pubmed/11015620

29. Alkharusi A, Lesma E, Ancona S, Chiaramonte E, Nystrom T, Gorio A, et al. Role of Prolactin Receptors in Lymphangiolyiomyomatosis. PLoS ONE. Public Library of Science; 2016; 11: e0146653. Available: https://doi.org/10.1371/journal.pone.0146653

30. Goffin V, Kelly P a. The prolactin/growth hormone receptor family: structure/function relationships. Journal of Mammary Gland Biology and Neoplasia. 1997; 2: 7–17. Available: http://www.ncbi.nlm.nih.gov/pubmed/10887515

31. Saini U, Naidu S, Elnaggar AC, Bid HK, Wallbillich JJ, Bixel K, et al. Elevated STAT3 expression in ovarian cancer patients. PLoS ONE. Public Library of Science; 2011; 8: 597–607. Available: http://dx.doi.org/10.1038/nurol.2011.143

32. Rahbar A, Alkharusi A, Costa H, Pantalone MR, Kostopoulos ON, Cui HL, et al. Human cytomegalovirus infection induces high expression of prolactin and prolactin receptors in ovarian cancer. Biology of Reproduction. 2020; 9. https://doi.org/10.3390/biology9030044

33. Tran-Thanh D, Ameson NC, Pintillie M, Delaliassi A, Warren KS, Bane A, et al. Amplification of the prolactin receptor gene in mammary lobular neoplasia. Breast cancer research and treatment. Netherlands; 2011; 128: 31–40. https://doi.org/10.1007/s10549-010-1025-6

34. Sanati S, Watson MA, Salavaggione AL, Humphrey PA. Gene expression profiles of ductal versus acinar adenocarcinoma of the prostate. Modern Pathology. Nature Publishing Group; 2009; 22: 1273–1279. https://doi.org/10.1038/modpathol.0009.103

35. Kong X, Wu W, Yuan Y, Pandey V, Wu Z, Lu X, et al. Human growth hormone and human prolactin function as autocrine/paracrine promoters of progression of hepatocellular carcinoma. Oncotarget. 2016; 7. https://doi.org/10.18632/oncotarget.8781

36. Shemanoko CS. Prolactin receptor in breast cancer: Marker for metastatic risk. Journal of Molecular Endocrinology. 2016. pp. R153–R165. https://doi.org/10.1530/JME-16-0150

37. Saini U, Naidu S, Elmaggar AC, Bid HK, Walbillich JJ, Bixel K, et al. Elevated STAT3 expression in ovarian cancer ascertains promides invasion and metastasis: A potential therapeutic target. Oncogene. 2017; 36: 168–181. https://doi.org/10.1038/onc.2016.197

38. Chen H, Ye D, Xie X, Chen B, Lu W. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecologic Oncology. 2004; 94: 630–635. https://doi.org/10.1016/j.ygyno.2004.05.056

39. Min H, Wei-Hong Z. Constitutive activation of signal transducer and activator of transcription 3 in epithelial ovarian carcinoma. Journal of Obstetrics and Gynaecology Research. 2009; 35: 918–925. https://doi.org/10.1111/j.1447-0756.2009.01045.x

40. Tripathi A, Sodhi A. Prolactin-induced production of cytokines in macrophages in vitro involves JAK/STAT and JNK MAPK pathways. International Immunology. 2008; 20: 327–336. https://doi.org/10.1093/intimm/dxm145

41. López-Rincón G, Pereira-Suárez AL, Del Toro-Areola S, Sánchez-Hernández PE, Ochoa-Zarzosa A, Muñoz-Valle JF, et al. Lipopolysaccharide induces the expression of an autocrine prolactin loop enhancing inflammatory response in monocytes. Journal of Inflammation (United Kingdom). 2013; 10. https://doi.org/10.1186/1476-9255-10-24

42. Cleveneger C V., Zheng J, Jablonski EM, Galbaugh TL, Fang F. From bench to bedside: Future potential for the translation of prolactin inhibitors as breast cancer therapeutics. Journal of Mammary Gland Biology and Neoplasia. 2008; 13: 147–156. https://doi.org/10.1007/s10911-008-9074-8

43. Goffin V, Bemichtein S, Touraine P, Kelly PA. Development and potential clinical uses of human prolactin receptor antagonists. Endocrine Reviews. 2005. pp. 400–422. https://doi.org/10.1210/er.2004-0016

44. Goffin V, Hoang DT, Bogorad RL, Nevalainen MT. Prolactin regulation of the prostate gland: a female player in a male game. Nat Rev Urol. Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.; 2011; 8: 597–607. Available: http://dx.doi.org/10.1038/nrurol.2011.143
45. Sordella R, Bell DW, Haber D a, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science (New York, NY). 2004; 305: 1163–1167. https://doi.org/10.1126/science.1101637 PMID: 15284455

46. Roos A, Dhruv HD, Peng S, Inge LJ, Tuncali S, Pineda M, et al. EGFRvIII–Stat5 signaling enhances glioblastoma cell migration and survival. Molecular Cancer Research. 2018; 16: 1185–1195. https://doi.org/10.1158/1541-7786.MCR-18-0125 PMID: 29724813

47. Wu CJ, Sundararajan V, Sheu BC, Huang RYJ, Wei LH. Activation of STAT3 and STAT5 signaling in epithelial ovarian cancer progression: Mechanism and therapeutic opportunity. Cancers. 2020. https://doi.org/10.3390/cancers121010024 PMID: 31861720

48. Shi X, Xiao L, Mao X, He J, Ding Y, Huang J, et al. miR-205-5p Mediated Downregulation of PTEN Contributes to Cisplatin Resistance in C13K Human Ovarian Cancer Cells. Frontiers in Genetics. 2018; 9. https://doi.org/10.3389/fgene.2018.00555 PMID: 30510566

49. Wang Z, Ting Z, Li Y, Chen G, Lu Y, Hao X. microRNA-199a is able to reverse cisplatin resistance in human ovarian cancer cells through the inhibition of mammalian target of rapamycin. Oncology Letters. 2013; 6: 789–794. https://doi.org/10.3892/ol.2013.1448 PMID: 24137412

50. Lee JH, Huynh M, Silhavy JL, Kim S, Dixon-Salazar T, Heiberg A, et al. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. Nature Genetics. 2012; 44: 941–945. https://doi.org/10.1038/ng.2329 PMID: 22729223

51. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102: 802–807. https://doi.org/10.1073/pnas.0408864102 PMID: 15647370

52. Alkharusi A, Lesma E, Ancona S, Chiaramonte E, Nyström T, Gorial A, et al. Role of prolactin receptors in lymphangioleiomyomatosis. PLoS ONE. 2016; 11. https://doi.org/10.1371/journal.pone.0146653 PMID: 26765335

53. Bonneterre J, Mauriac L, Weber B, Roche H, Fargeot P, Tubiana-Hulin M, et al. Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: Results of a double blind multicentre clinical trial. European Journal of Cancer and Clinical Oncology. Elsevier; 1988; 24: 1851–1853. https://doi.org/10.1016/0277-5379(88)90097-1 PMID: 3065085

54. Yu S, Alkharusi A, Norstedt G, Gräslund T. An in vivo half-life extended prolactin receptor antagonist can prevent STAT5 phosphorylation. PLoS ONE. 2019; 14.

55. Kelly MP, Hickey C, Makonnen S, Coetzee S, Jalal S, Wang Y, et al. Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody–Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers. Molecular Cancer Therapeutics. 2017; 16: 1299 LP– 1311. https://doi.org/10.1158/1535-7163.MCT-16-0839 PMID: 28377489

56. Agarwal N, Machiels J, Suárez C, Lewis N, Higgins M, Wisinski K, et al. Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer. The Oncologist. 2016; 21: 535. https://doi.org/10.1634/theoncologist.2015-0502 PMID: 27091421

57. Tang MW, Garcia S, Gerlag DM, Tak PP, Reedquist KA. Insight into the Endocrine System and the Immune System: A Review of the Inflammatory Role of Prolactin in Rheumatoid Arthritis and Psoriatic Arthritis [Internet]. Frontiers in Immunology. 2017. p. 720. Available: https://doi.org/10.3389/fimmu.2017.00720 PMID: 28690611